How does Homopeptide compare to Zhuhai Kerui Biotechnology on documentation quality?

Stated plainly: Homopeptide · Zhuhai Kerui Biotechnology.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

Under what conditions does the answer flip?

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

The relevant detail is that sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

One laboratory, one method, one submission. Otherwise it is not a comparison.

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

Use a fixed documentation checklist rather than an impression.

This is the question where methodology matters more than the conclusion.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Price per milligram of measured peptide, not per milligram of label claim.

Ratings on this site are ours alone and are deliberately not reconciled with anyone else's.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.

Compare content, not purity. Purity clusters and content does not.

edited 11 Feb 2025 by Dr_Nadia_Farsi — fixed an arithmetic slip in the third paragraph